Vikram Bhattacharjee, PhD,
Primary Scientist


Vikram studied Genetics at the University of Georgia and earned his PhD from the University of South Carolina in 2008. 

Previous to becoming Evol's Primary Scientist, Vikram worked as a Graduate Student at the University of South Carolina, under Dr. Alan S. Waldman from 2003 to 2008. He then worked as a Postdoctoral Research Associate at Fox Chase Cancer Center in the laboratory of Dr. Tim J. Yen from 2008 to 2014. 

He was awarded the 2010 Samuel Stroum Fellowship, Pancreatic Cancer Action Network/AACR, and holds multiple patents on novel therapeutic drug combinations against late-stage cancers.

Dr. Andrews

Selected Publications:

Ross KC, Chin KF, Kim D, Marion CD, Yen TJ, Bhattacharjee V. Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.
Oncotarget. 2018 Jan 29;9(17):13324-13336.  

Ross KC, Andrews AJ, Marion CD, Yen TJ, Bhattacharjee V. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Mol Cancer Ther. 2017 Aug;16(8):1596-1609. 

Ursu O, Gosline SJC, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens.
PLoS One. 2017 Oct 12;12(10): e0185650.

Bhattacharjee V, Zhou Y, Yen TJ. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Cell Cycle. 2014;13(24):3839-56.